secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2024-06-27T23:59:59+00:00
Accession:  0001558370-24-009526
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus sells YUSIMRY (adalimumab-aqvh) to HKF for $40M upfront cash
--------------------------------------------------------------------

- Upfront all-cash consideration of $40M; closing occurred June 26, 2024.
- HKF's subsidiary Meitheal will commercialize YUSIMRY in the U.S.
- HKF assumes $17M in inventory purchase commitments; Coherus retains certain excluded assets/liabilities.
- Divestiture aligns with Coherus' strategic focus on oncology; proceeds to bolster cash position.
- Coherus retains oncology assets including LOQTORZI, UDENYCA franchise, and immuno-oncology pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837024009526/0001558370-24-009526-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837024009526/chrs-20240626x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-009526

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer